Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Study demonstrated that famotidine to inhibit gastrointestinal disorders in patients with cardiovascular diseases
Subscribe to our email newsletter
Astellas Pharma’ FAMOUS trial, in which Gaster (famotidine) was effective on the prevention of peptic ulcers in uses of low-dose aspirin, was observed and reported in the medical journal – The Lancet, published on July 11, 2009.
Dr. Ali Taha, the investigator and the first author of FAMOUS trial, Clinical Director of Crosshouse Hospital, UK, said: “Thanks to low-dose aspirin, the mortality rate resulting from myocardial infarction and stroke is steadily dropping. How we control severe complications such as gastrointestinal haemorrhage and perforation holds the key to continuing to provide effective treatment safely.
“The results of FAMOUS study demonstrated that famotidine can inhibit gastrointestinal disorders in patients with cardiovascular diseases, cerebrovascular diseases or diabetes who are taking low-dose aspirin,” he added.
Reportedly, Gaster was launched as the first H2 receptor blocker originated in Japan in July 1985. Gaster is indicated for gastric ulcers, duodenal ulcers and gastric mucosal lesions associated with acute gastritis and chronic gastritis. It is now prescribed in 1.2 million patients daily.